XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
0.810
-0.020 (-2.41%)
Real-time:   3:30PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.81 - 0.85
52 week 0.79 - 5.95
Open 0.85
Vol / Avg. 2.71M/8.98M
Mkt cap 97.35M
P/E     -
Div/yield     -
EPS -0.50
Shares 117.82M
Beta 2.93
Inst. own 70%
Aug 6, 2015
Q2 2015 XOMA Corp Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 XOMA Corp Earnings Release - 4:00PM EDT - Add to calendar
Jul 22, 2015
XOMA Conference Call - Results From Phase 3 EYEGUARD(TM)-B Study - Webcast
May 21, 2015
XOMA Corp Annual Shareholders Meeting
May 7, 2015
Q1 2015 XOMA Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 XOMA Corp Earnings Release
May 6, 2015
XOMA Corp at Credit Suisse Antibody Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -819.24% -203.02%
Operating margin -851.49% -433.75%
EBITD margin - -423.24%
Return on average assets -103.89% -34.13%
Return on average equity - -
Employees 183 -
CDP Score - -

Address

2910 7th St
BERKELEY, CA 94710-2700
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Company's lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcet's disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcet's disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas M. Burns Chief Financial Officer
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Tom Klein Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 88
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 80
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 62
Bio & Compensation  - Reuters
Timothy P. Walbert Independent Director
Age: 48
Bio & Compensation  - Reuters